This article covers Lu-177 PSMA therapy for men with metastatic castration-resistant prostate cancer (mCRPC), a cancer that has spread and doesn't respond to hormone therapy anymore. This guide shows what treatment actually costs in India.
A full course of lutetium Lu-177 vipivotide tetraxetan (brand name Pluvicto) usually involves four to six cycles spaced six to eight weeks apart. In India, the total cost for the drug, hospital fees, and scans usually falls between USD 20,000 and USD 48,000, depending on the center and number of cycles. In the United States, the drug alone costs about USD 42,500 to USD 51,000 per cycle, making a six-cycle course over USD 250,000 before hospital or scan fees. This gap is why patients from the GCC, East Africa, South Asia, and beyond are traveling to India for this treatment.
What Is Lu-177 PSMA Therapy and Who Qualifies?
Lu-177 PSMA therapy is a radioligand therapy. It works by attaching a radioactive molecule called lutetium-177 to a targeting agent that seeks out PSMA (prostate-specific membrane antigen), a protein on prostate cancer cells. Once attached to a cancer cell, the radiation damages that cell from the inside and spares most of the surrounding healthy tissue.
To be eligible, your cancer cells must have enough PSMA to show up on a PSMA-PET scan. If your scan shows enough PSMA and your kidney and blood test results are in the right range, treatment can begin. For a plain-language explanation, see our guide on how Lu-177 PSMA works and what theranostics means for prostate cancer.
The phase 3 VISION trial, published in the New England Journal of Medicine, showed that adding Lu-177 PSMA-617 to standard treatment reduced death risk by 38% and slowed cancer growth in men with PSMA-positive mCRPC who had already received hormone therapy and chemotherapy. Median overall survival was 15.3 months in the treatment group versus 11.3 months in the standard group. This led to FDA approval of Pluvicto in 2022, with expanded approvals for earlier disease in 2025 and 2026.
Why Is Lu-177 PSMA Therapy More Affordable in India?
- Domestic production of lutetium-177: India makes lutetium-177 locally, which removes the international supply-chain cost added in countries that import radiopharmaceuticals.
- Lower hospital overhead: Staff salaries, facility costs, and administrative expenses at Indian hospitals are much lower than in the US or UAE.
- Competition among established centers: Major hospitals in Mumbai, Delhi, Chennai, Hyderabad, and Ahmedabad compete for international patients, which keeps pricing transparent and competitive.
- Self-pay pricing without insurer markup: International self-pay patients in India often pay closer to the real cost of production and administration, unlike prices in the US.
Choosing the right center matters as much as comparing costs. Our guide on evaluating a Lu-177 PSMA treatment center in India walks through the credentials and questions to ask before committing.
How Does Lu-177 PSMA Cost in India Compare with Other Countries?
| Cost Factor | India | USA | UAE / GCC |
|---|---|---|---|
| Drug and admin cost per cycle | USD 5,000-8,000 (hospital quotes, 2024-2025) | About USD 42,500-51,000 (Pluvicto wholesale price, Jan 2026) | Not widely available; few centers offer it |
| Typical full course (4-6 cycles) | About USD 20,000-48,000 | About USD 170,000-306,000 (drug cost only) | Varies - ask for a written quote |
| PSMA-PET scan (eligibility) | Available; costs less than Western hospitals | USD 1,500-3,000 (separate from treatment cost) | Available at some centers; costs vary |
| Approximate wait for first treatment | 2-6 weeks after confirmed eligibility | 6-12 weeks or more at many centers | Limited access; longer waits usually |
| Days needed per cycle visit | 3-5 days per visit | Usually 1-2 days (as an outpatient) | Varies by center |
India cost ranges are based on hospital quotes from established Indian nuclear medicine centers (2024-2025). USA figures are the published wholesale price for Pluvicto at about USD 42,500-51,000 per cycle as of early 2026. All numbers are estimates; ask for a written itemized quote before traveling.
The main point: the drug alone in the United States costs more per cycle than a full course in India usually costs altogether. For patients paying out of pocket, India can determine whether they can afford this treatment.
What Does the Full India Budget Look Like?
Drug and Hospital Fees
The largest cost is the drug plus the hospital fee for handling and administering it. Most established Indian centers bundle these into a single per-cycle price that covers the drug, its preparation, injection, monitoring after injection, and nursing care for that day. Across reputable centers in 2024-2025, hospital quoted prices generally fall between USD 5,000 and USD 8,000 per cycle. For four to six cycles, your total drug and hospital cost would be about USD 20,000 to USD 48,000. Always ask for a written itemized quote - not a verbal estimate - before you book your flight.
Imaging and Lab Tests
Before your first cycle, you need a current PSMA-PET scan to confirm you're eligible. If your most recent scan is more than three to six months old, you need a new one. India has good availability of Ga-68 PSMA-PET/CT at established centers, with lower costs than Western hospitals. Between cycles, you'll get routine blood tests to monitor kidney function and blood counts. These are low-cost in India and sometimes included in the cycle package. Our guide on preparing for your PSMA-PET scan for Lu-177 eligibility explains what to expect.
Accommodation and Living Costs
Cycles are spaced six to eight weeks apart. Most international patients choose one of two approaches: fly back home between cycles, or stay in India for the full course.
If you stay in India throughout, service apartments near major cancer centers in Mumbai, Delhi, Chennai, and Hyderabad typically cost USD 30 to USD 80 per night for one or two people. A companion is important, especially for the first 48 hours after each injection when radiation safety rules apply. Day-to-day costs for meals and local transport for two people usually come to USD 25 to USD 45 per day, which is very low compared to Western countries.
If you fly back between cycles, you save on housing costs but pay for flights each time. Our article on planning your India trip for Lu-177 PSMA therapy covers this stay-versus-fly choice in detail.
Many men with mCRPC are on long-term androgen deprivation therapy (ADT), which can cause bone loss over time. If your care team talks about bone health during treatment, Ayurnomics offers Ayurvedic products for joint and bone health that you can use with your medical treatment.
Visa and Administrative Costs
India offers a Medical Visa category for international patients, usually valid for up to one year with multiple entries - a good option for a multi-cycle course. Most Indian hospitals with international patient offices can provide the visa invitation letter you need for your application. Budget some money for visa fees, which vary by country, and for translating documents or preparing medical records before travel.
Realistic Total Budget
For a patient from the GCC, East Africa, or South Asia planning four cycles and staying in India throughout:
- Drug and hospital fees (4 cycles): about USD 20,000 to USD 32,000
- PSMA-PET scan and labs done in India: about USD 400 to USD 800
- Service apartment and meals for patient and one companion over 3-4 months: about USD 4,000 to USD 10,000
- Flights: costs vary by where you're from - pay for this separately
Altogether (excluding flights), many international patients report a total cost between USD 25,000 and USD 45,000 for a full course. These are estimates based on what patients have paid and hospital quotes. Your actual cost will depend on which hospital you choose, how many cycles you need, and where you stay. Add 15 to 20 percent more to your estimate as a cushion for unexpected costs.
Confirm Eligibility Before You Book Anything
The most important step before booking a flight is confirming you're a candidate for Lu-177 PSMA therapy. This therapy only works if your cancer cells have enough PSMA, and a current PSMA-PET scan determines whether you qualify. If your most recent scan is more than three to six months old, you need to check your eligibility again.
Before you spend money on travel and logistics, you can request an eligibility review through Art of Healing Cancer. Send your PSMA-PET report, recent PSA values, pathology results, and treatment history for assessment. If you're eligible, the team can connect you with a center in India. If you're not currently eligible, the team can tell you what other treatments might work. This way, you'll know before spending money on flights whether treatment is the right option for you now.
What If Cost Is Still a Barrier?
Some patients ask whether they can start with fewer cycles to save money. Most oncologists recommend planning a full course from the start, because the trial data shows results over four to six cycles. If cost is still a barrier, talk honestly with the treatment center before you arrive. Some offer payment plans spread over time. Our guide on financing Lu-177 PSMA treatment in India covers payment plans, medical loans, and questions to ask before you commit.
What the Budget Does Not Cover
These numbers don't include emergency medical care for complications, extra medicine or hospital stays for side effects, follow-up scans to check your progress, hormone therapy that continues with treatment, or travel health insurance. Get travel health insurance. Plan for it in your budget.
When to Talk to Your Doctor
Talk to your oncologist or nuclear medicine specialist about traveling to India for treatment. Ask whether your current scans and labs are recent enough to confirm eligibility, whether this therapy is the right next step for you, or whether your kidney function or blood count results might affect your candidacy.
You can submit your records for a remote eligibility review through the Lutetium Therapy contact page. If Lu-177 PSMA therapy doesn't fit your situation right now, the team can advise on other treatments to discuss with your oncologist.
This article is for general information only and not medical advice. Always talk to your oncologist or care team about your specific situation.
Frequently asked questions
How many cycles of Lu-177 PSMA therapy does a patient typically need in India?
Most patients receive four to six cycles, spaced six to eight weeks apart. The exact number depends on how well the cancer is responding, your kidney function, and your blood counts after each injection. Your nuclear medicine team will review you after each cycle before recommending the next.
Can I do my PSMA-PET scan before traveling to India?
Yes, and this is generally recommended. If you have a recent PSMA-PET scan from a recognised center in your home country, you can send the images and report for a remote eligibility assessment before booking travel. Most Indian centers accept scans done within the past three to six months. Getting the scan done locally - if it is available where you are - can save time and may avoid the cost of repeating it in India.
Does the per-cycle price in India include the drug and the hospital administration fee?
At most established Indian nuclear medicine centers, the quoted per-cycle price is an all-in figure covering the radioactive drug, its preparation, administration in the nuclear medicine suite, post-injection monitoring, and basic nursing care. Some centers charge the drug and the administration fee separately. Always ask for a written, itemised breakdown of exactly what is and is not included before you agree to treatment.
What currency should I use to plan my budget for treatment in India?
Most Indian hospitals dealing with international patients quote prices in US dollars (USD) for transparency, though you will pay in Indian rupees on-site at the prevailing exchange rate. Check the exchange rate close to the time of payment and build a small buffer into your budget to account for currency fluctuation.
What happens if my PSMA-PET scan shows my cancer does not express enough PSMA?
If the scan shows low or absent PSMA expression, Lu-177 PSMA therapy is unlikely to be effective and most centers will not proceed with treatment. This is not the end of all options - your oncologist can review other available lines of therapy for mCRPC. Completing a remote eligibility review before you travel can identify this situation early and avoid a costly trip.
Is the quality of Lu-177 PSMA therapy at Indian centers comparable to Western hospitals?
Several Indian nuclear medicine centers have established track records with Lu-177 PSMA therapy and follow internationally recognised protocols. However, quality varies between institutions. Look for hospitals with dedicated nuclear medicine departments, documented experience with international patients, and verifiable treatment volumes. An independent second opinion on center selection is worthwhile before committing.
